Skip to main content

Table 1 Baseline demographic, clinical, functional, and x-ray characteristics of patients

From: Bone formation rather than inflammation reflects Ankylosing Spondylitis activity on PET-CT: a pilot study

  Low disease activity (BASDAI < 4) (n= 5) High disease activity (BASDAI ≥ 4) (n= 7)
Males/females 4/1 3/4
HLA-B27-positive, percentage 100 57
Age, years 31.0 (25-50) 41.0 (24-56)
Duration since diagnosisa, years 2.0 (0-4) 3.0 (0-20)
Duration of symptomsb, years 12.0 (7-19) 12.0 (1-32)
BASDAI (0-10) 1.7 (0.7-2.2) 6.9 (5.1-9.8)
ESR, mm/hour 14.0 (4-19) 23.0 (2-30)
Sacroiliitis (0-8) 5.0 (4-6) 5.0 (4-7)
m-SASSS (0-72) 2.5 (0-6) 1.6 (0-14)
BASRI-hip (0-8) 1.2 (0-2) 0.75 (0-2)
  1. Values are presented as median (range). aDuration since diagnosis (in years), from definite ankylosing spondylitis (AS) diagnosis according to the modified New York criteria. bDuration of symptoms (in years), from the start of inflammatory back pain. BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASRI-hip, Bath Ankylosing Spondylitis Index for the Hip (0 to 4, sum of right and left scores); ESR, erythrocyte sedimentation rate; HLA-B27, human leukocyte antigen-B27; m-SASSS, modified Stoke Ankylosing Spondylitis Spinal Score; Sacroiliitis, sacroiliitis scoring according to the radiographic modified New York criteria (0 to 4, sum of right and left scores).